Bitcoin Is Just Getting Started, Says Billion Dollar Investor | Moez Kassam
10/20/2026 · 62 min · transcript via mlx
Tags
Key topics
— Moez Kassam discusses how to profit from hype cycles by identifying themes early, understanding sentiment, and knowing when to exit before peak euphoria.
— Bitcoin evolution from deal-making opportunity to institutional asset class adoption, with treasury companies becoming a major recent theme.
— AI valuations remain frothy despite legitimate disruption; competing with large funds on mega-cap picks like Tesla and SpaceX offers no edge.
— Korean memory manufacturers (Samsung, SK Hynix) represent significant opportunity as sentiment has turned negative despite strong forward earnings.
— Long activism replacing short selling as a more effective strategy in fragmented smaller-cap markets; Lionsgate and Moderna are current examples.
— Prediction markets serve as a reliable signal for insider knowledge; social media sentiment analytics inform retail investor positioning.
Market & price signals
— S&P 500 trading only 2% below all-time highs while Russell 2000 and momentum names down 20–25%, indicating divergence between large-cap and retail-driven trades.
— Second-largest put buying in history occurred recently (NASDAQ third-largest), suggesting potential for forced covering and upside if market doesn't decline.
— Korean semiconductor stocks (Samsung, SK Hynix) rallied from bust phase; treasury company discounts to NAV now present arbitrage opportunity, especially Strive's recently issued preferred equity at 90 (target 100).
— Moderna stock up ~100% on cancer trial hype; binary event expected within days likely to disappoint retail expectations and reset valuation.
— CoreWeave experienced record put buying in single day, followed by reversal; tactical opportunity in dislocations during panic selling.
Actionable insights
— Focus on finding your edge by staying in smaller, less-crowded market segments where large institutional funds cannot compete due to minimum size constraints; avoid mega-cap consensus trades.
— Use prediction markets and social media sentiment as a data input (not the sole signal) to gauge where retail and insider positioning diverges from fair value, especially around binary earnings events.
— Recognize when euphoria is peaking by monitoring how many retail investors are discussing a theme and allocating accordingly; hold for 7–9 innings rather than chasing the full trade to the end.
Episode sponsorships
Paid placements mentioned in this episode. BTC Pods is not sponsored by or affiliated with these advertisers. Links are included so you can find offers mentioned on the show.
— Indeed is highlighting how Sponsored Jobs can help businesses find quality talent faster. Get a $75 sponsored job credit at indeed.com/podcast to boost your job post and reach the right candidates.
— Arch Public is an agentic trading platform that automates buying and selling of your preferred crypto strategies. Sign up at https://www.archpublic.com for free—no hidden fees, just smarter trading.
— Galaxy One is a financial technology platform built for people who want their cash working harder. Open an account with promo code POMP and deposit $10,000 to earn a $3,000 bonus. See site for promotion details at https://go.galaxy.app/HMiq/p57n69yy. Galaxy Premium Yield is an investment note issued by Galaxy Digital LP and guaranteed by Galaxy Digital Holdings LP. It is not a bank deposit, is unsecured, and is not FDIC or SIPC insured. U.S. accredited investors only.
— Fitnexa SomniPods 3 are ultra-thin sleep earbuds built for all-night comfort with up to 42dB of noise cancellation, sleep tracking, and personalized AI insights. Use code POMP10 for $10 off at https://www.fitnexa.com.
— Investor Health is a telehealth platform providing clinician-prescribed protocols for weight, metabolism, energy, and longevity, delivered to your door in 48–72 hours with no office visits or referrals. Programs start at $149 per month. Visit http://www.InvestorHealth.com/pomp. Investor Health is a telehealth platform, not a medical provider; compounded medications are not FDA-approved and individual results may vary.